Insight into Retinal Dystrophy: Understanding Features and Treatment Strategies

Main Article Content

Asma Arshad
Muhammad Aneeq Alyas
Sana Arshad
Usman Arshad

Abstract

Retinal dystrophies such as; Retinitis pigmentosa, Congenital Stationary Night Blindness, stargartds disease, lebers congenital amaurosis, and others; present with significant visual impairments due to various genetic mutations affecting retinal function and photoreceptor maintenance. This review explores the diverse landscape of retinal dystrophies, categorizing subtypes based on affected cell types. It sheds light on the clinical characteristics, diagnostic techniques, and complex genetic underpinnings of many illnesses. The study emphasizes the significance of the genetic landscape and enhanced diagnostic tools for prognosis. It also looks at newer forms of treatment, such as gene treatments and pharmaceutical approaches, providing a succinct summary of the developing field. This review, aimed at researchers and clinicians, is a useful tool for comprehending and treating retinal dystrophies.

Article Details

How to Cite
Arshad, A., Alyas, M. A., Arshad, S., & Arshad, U. (2024). Insight into Retinal Dystrophy: Understanding Features and Treatment Strategies. Journal of Health and Rehabilitation Research, 4(2), 175–182. https://doi.org/10.61919/jhrr.v4i2.784
Section
Articles
Author Biographies

Asma Arshad, Quaid-i-Azam University Islamabad Pakistan

Department of Zoology, Quaid-i-Azam University, Islamabad, Pakistan

Muhammad Aneeq Alyas, Rabia Eye Clinic Toba Tek Singh Pakistan

Senior Optometrist, Rabia Eye Clinic, Toba Tek Singh, Pakistan

Sana Arshad, Aziz Fatimah Medical and Dental College Faisalabad Pakistan

Aziz Fatimah Medical and Dental College, Faisalabad, Pakistan

Usman Arshad, Shalamar Medical and Dental College Lahore Pakistan.

Shalamar Medical and Dental College Lahore, Pakistan.

References

Bertelsen M, Jensen H, Bregnhøj JF, Rosenberg T. Prevalence of generalized retinal dystrophy in Denmark. Ophthalmic epidemiology. 2014;21(4):217-23.

Hamel C. Retinitis pigmentosa. Orphanet journal of rare diseases. 2006;1(1):1-12.

Bowne SJ, Sullivan LS, Blanton SH, Cepko CL, Blackshaw S, Birch DG, et al. Mutations in the inosine monophosphate dehydrogenase 1 gene (IMPDH1) cause the RP10 form of autosomal dominant retinitis pigmentosa. Human molecular genetics. 2002;11(5):559-68.

Chuang J-Z, Hsu Y-C, Sung C-H. Ultrastructural visualization of trans-ciliary rhodopsin cargoes in mammalian rods. Cilia. 2015;4(1):1-15.

Bunker CH, Berson EL, Bromley WC, Hayes RP, Roderick TH. Prevalence of retinitis pigmentosa in Maine. American journal of ophthalmology. 1984;97(3):357-65.

Chawla H, Vohra V. Retinal dystrophies. StatPearls [Internet]: StatPearls Publishing; 2023.

Talib M, Boon CJ. Retinal dystrophies and the road to treatment: clinical requirements and considerations. Asia-pacific Journal of Ophthalmology (Philadelphia, Pa). 2020;9(3):159.

Nash BM, Wright DC, Grigg JR, Bennetts B, Jamieson RV. Retinal dystrophies, genomic applications in diagnosis and prospects for therapy. Translational pediatrics. 2015;4(2):139.

Hamel CP. Cone rod dystrophies. Orphanet J Rare Dis. 2007;2:7.

Lamb TD. Why rods and cones? Eye. 2016;30(2):179-85.

Thiadens AA, Phan TML, Zekveld-Vroon RC, Leroy BP, van Den Born LI, Hoyng CB, et al. Clinical course, genetic etiology, and visual outcome in cone and cone–rod dystrophy. Ophthalmology. 2012;119(4):819-26.

Ducroq D, Rozet J-M, Gerber S, Perrault I, Barbet F, Hanein S, et al. The ABCA4 gene in autosomal recessive cone-rod dystrophies. The American Journal of Human Genetics. 2002;71(6):1480-2.

Simunovic MP, Moore AT. The cone dystrophies. Eye. 1998;12(3):553-65.

Remmer MH, Rastogi N, Ranka MP, Ceisler EJ. Achromatopsia: a review. Current Opinion in Ophthalmology. 2015;26(5):333-40.

Neitz J, Neitz M. The genetics of normal and defective color vision. Vision research. 2011;51(7):633-51.

Hirji N, Aboshiha J, Georgiou M, Bainbridge J, Michaelides M. Achromatopsia: clinical features, molecular genetics, animal models and therapeutic options. Ophthalmic genetics. 2018;39(2):149-57.

Poloschek C, Kohl S. Achromatopsia. Der Ophthalmologe. 2010;107:571-82.

Michaelides M, Hunt D, Moore A. The cone dysfunction syndromes. The British journal of ophthalmology. 2004;88(2):291.

Poloschek CM, Kohl S. [Achromatopsia]. Ophthalmologe. 2010;107(6):571-80; quiz 81-2.

Tsang SH, Sharma T. Rod monochromatism (achromatopsia). Atlas of Inherited Retinal Diseases. 2018:119-23.

Solaki M, Baumann B, Reuter P, Andreasson S, Audo I, Ayuso C, et al. Comprehensive variant spectrum of the CNGA3 gene in patients affected by achromatopsia. Human mutation. 2022;43(7):832-58.

Weisschuh N, Sturm M, Baumann B, Audo I, Ayuso C, Bocquet B, et al. Deep‐intronic variants in CNGB3 cause achromatopsia by pseudoexon activation. Human mutation. 2020;41(1):255-64.

Felden J, Baumann B, Ali M, Audo I, Ayuso C, Bocquet B, et al. Mutation spectrum and clinical investigation of achromatopsia patients with mutations in the GNAT2 gene. Human Mutation. 2019;40(8):1145-55.

Andersen MKG, Bertelsen M, Grønskov K, Kohl S, Kessel L. Genetic and Clinical Characterization of Danish Achromatopsia Patients. Genes. 2023;14(3):690.

Danish E, Alhashem A, Aljehani R, Aljawi A, Aldarwish MM, Al Mutairi F, et al. Phenotype and genotype of 15 Saudi patients with achromatopsia: A case series. Saudi Journal of Ophthalmology. 2023;37(4):301-6.

Kohl S, Varsanyi B, Antunes GA, Baumann B, Hoyng CB, Jägle H, et al. CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia. European Journal of Human Genetics. 2005;13(3):302-8.

Ziccardi L, Cordeddu V, Gaddini L, Matteucci A, Parravano M, Malchiodi-Albedi F, et al. Gene therapy in retinal dystrophies. International journal of molecular sciences. 2019;20(22):5722.

Broadgate S, Yu J, Downes SM, Halford S. Unravelling the genetics of inherited retinal dystrophies: Past, present and future. Progress in retinal and eye research. 2017;59:53-96.

Kohl S, Jägle H, Wissinger B, Zobor D. Achromatopsia. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle

Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.

Remmer MH, Rastogi N, Ranka MP, Ceisler EJ. Achromatopsia: a review. Curr Opin Ophthalmol. 2015;26(5):333-40.

Schornack MM, Brown WL, Siemsen DW. The use of tinted contact lenses in the management of achromatopsia. Optometry-Journal of the American Optometric Association. 2007;78(1):17-22.

Kellner U, Wissinger B, Tippmann S, Kohl S, Kraus H, Foerster MH. Blue cone monochromatism: clinical findings in patients with mutations in the red/green opsin gene cluster. Graefe's Archive for Clinical and Experimental Ophthalmology. 2004;242:729-35.

Birtel J, Gliem M, Mangold E, Müller PL, Holz FG, Neuhaus C, et al. Next-generation sequencing identifies unexpected genotype-phenotype correlations in patients with retinitis pigmentosa. PloS one. 2018;13(12):e0207958.

Orphanet. Prevalence and incidence of rare diseases: Bibliographic data. Inserm; 2021. p. 35.

Kocaaga A, Aköz İÖ, Demir NU, Paksoy B. Identification of novel variants in retinitis pigmentosa genes by whole-exome sequencing. Revista da Associação Médica Brasileira. 2023;69:e20221073.

Daiger SP, Bowne SJ, Sullivan LS. Perspective on genes and mutations causing retinitis pigmentosa. Archives of ophthalmology. 2007;125(2):151-8.

Cortinhal T, Santos C, Vaz-Pereira S, Marta A, Duarte L, Miranda V, et al. Genetic profile of syndromic retinitis pigmentosa in Portugal. Graefe's Archive for Clinical and Experimental Ophthalmology. 2024:1-15.

Kamde SP, Anjankar A. Retinitis Pigmentosa: Pathogenesis, Diagnostic Findings, and Treatment. Cureus. 2023;15(10).

Cross N, van Steen C, Zegaoui Y, Satherley A, Angelillo L. Retinitis pigmentosa: Burden of disease and current unmet needs. Clinical Ophthalmology. 2022:1993-2010.

Cross N, van Steen C, Zegaoui Y, Satherley A, Angelillo L. Current and future treatment of retinitis pigmentosa. Clinical Ophthalmology. 2022:2909-21.

Wu KY, Kulbay M, Toameh D, Xu AQ, Kalevar A, Tran SD. Retinitis Pigmentosa: Novel Therapeutic Targets and Drug Development. Pharmaceutics. 2023;15(2):685.

Cross N, van Steen C, Zegaoui Y, Satherley A, Angelillo L. Current and Future Treatment of Retinitis Pigmentosa. Clin Ophthalmol. 2022;16:2909-21.

Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. The Lancet. 2006;368(9549):1795-809.

Huang SH, Pittler SJ, Huang X, Oliveira L, Berson EL, Dryja TP. Autosomal recessive retinitis pigmentosa caused by mutations in the α subunit of rod cGMP phosphodiesterase. Nature genetics. 1995;11(4):468-71.

Janecke AR, Thompson DA, Utermann G, Becker C, Hübner CA, Schmid E, et al. Mutations in RDH12 encoding a photoreceptor cell retinol dehydrogenase cause childhood-onset severe retinal dystrophy. Nature genetics. 2004;36(8):850-4.

McLaughlin ME, Sandberg MA, Berson EL, Dryja TP. Recessive mutations in the gene encoding the β–subunit of rod phosphodiesterase in patients with retinitis pigmentosa. Nature genetics. 1993;4(2):130-4.

Bareil C, Hamel C, Delague V, Arnaud B, Demaille J, Claustres M. Segregation of a mutation in CNGB1 encoding the β-subunit of the rod cGMP-gated channel in a family with autosomal recessive retinitis pigmentosa. Human genetics. 2001;108:328-34.

Thompson DA, Li Y, McHenry CL, Carlson TJ, Ding X, Sieving PA, et al. Mutations in the gene encoding lecithin retinol acyltransferase are associated with early-onset severe retinal dystrophy. Nature genetics. 2001;28(2):123-4.

Martínez Mir A, Paloma E, Allikmets R, Ayuso C, Río Td, Dean M, et al. Retinitis pigmentosa caused by a homozygous mutation in the Stargardt disease gene ABCR. 1998.

Bessant DA, Payne AM, Mitton KP, Wang Q-L, Swain PK, Plant C, et al. A mutation in NRL is associated with autosomal dominant retinitis pigmentosa. Nature genetics. 1999;21(4):355-6.

Coppieters F, Leroy BP, Beysen D, Hellemans J, De Bosscher K, Haegeman G, et al. Recurrent mutation in the first zinc finger of the orphan nuclear receptor NR2E3 causes autosomal dominant retinitis pigmentosa. The American Journal of Human Genetics. 2007;81(1):147-57.

Muniz A, Villazana-Espinoza ET, Hatch AL, Trevino SG, Allen DM, Tsin AT. A novel cone visual cycle in the cone-dominated retina. Experimental eye research. 2007;85(2):175-84.

Neveling K, Collin RW, Gilissen C, Van Huet RA, Visser L, Kwint MP, et al. Next‐generation genetic testing for retinitis pigmentosa. Human mutation. 2012;33(6):963-72.

Maguire AM, Bennett J, Aleman EM, Leroy BP, Aleman TS. Clinical perspective: treating RPE65-associated retinal dystrophy. Molecular Therapy. 2021;29(2):442-63.

MacLaren RE, Bennett J, Schwartz SD. Gene therapy and stem cell transplantation in retinal disease: the new frontier. Ophthalmology. 2016;123(10):S98-S106.

Huang C-H, Yang C-M, Yang C-H, Hou Y-C, Chen T-C. Leber’s congenital amaurosis: current concepts of genotype-phenotype correlations. Genes. 2021;12(8):1261.

Roy M, Fleisher RC, Alexandrov AI, Horovitz A. Reduced ADP off-rate by the yeast CCT2 double mutation T394P/R510H which causes Leber congenital amaurosis in humans. Communications Biology. 2023;6(1):888.

Perrault I, Rozet J-M, Gerber S, Ghazi I, Leowski C, Ducroq D, et al. Leber congenital amaurosis. Molecular genetics and metabolism. 1999;68(2):200-8.

Tsang SH, Sharma T. Leber congenital amaurosis. Atlas of inherited retinal diseases. 2018:131-7.

Kumaran N, Moore AT, Weleber RG, Michaelides M. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions. British journal of ophthalmology. 2017.

Cremers FP, van den Hurk JA, den Hollander AI. Molecular genetics of Leber congenital amaurosis. Human molecular genetics. 2002;11(10):1169-76.

Kumaran N, Moore A, Weleber R. Leber congenital amaurosis/early-onset severe retinal dystrophy: clinical features, molecular genetics and therapeutic interventions (vol 101, pg 1147, 2017). BRITISH JOURNAL OF OPHTHALMOLOGY. 2019;103(6):862-.

Chacon-Camacho OF, Zenteno JC. Review and update on the molecular basis of Leber congenital amaurosis. World Journal of Clinical Cases: WJCC. 2015;3(2):112.

Pontikos N, Arno G, Jurkute N, Schiff E, Ba-Abbad R, Malka S, et al. Genetic basis of inherited retinal disease in a molecularly characterized cohort of more than 3000 families from the United Kingdom. Ophthalmology. 2020;127(10):1384-94.

Flanders M, Lapointe M, Brownstein S, Little J. Keratoconus and Leber's congenital amaurosis: a clinicopathological correlation. Canadian Journal of ophthalmology Journal Canadien D'ophtalmologie. 1984;19(7):310-4.

McDougald DS, Kmiec E, Mills JA. Personalized models reveal mechanistic and therapeutic insights into CEP290-associated Leber congenital amaurosis. Stem Cell Investigation. 2016;3.

den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: genes, proteins and disease mechanisms. Progress in retinal and eye research. 2008;27(4):391-419.

Varela MD, de Guimaraes TAC, Georgiou M, Michaelides M. Leber congenital amaurosis/early-onset severe retinal dystrophy: current management and clinical trials. British Journal of Ophthalmology. 2021.

Astuti GD, Bertelsen M, Preising MN, Ajmal M, Lorenz B, Faradz SM, et al. Comprehensive genotyping reveals RPE65 as the most frequently mutated gene in Leber congenital amaurosis in Denmark. European Journal of Human Genetics. 2016;24(7):1071-9.

Hammond Jr BR, Wooten BR, Snodderly DM. Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. Vision research. 1996;36(18):3003-9.

Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nature Reviews Immunology. 2003;3(11):879-89.

van Genderen MM, Bijveld MM, Claassen YB, Florijn RJ, Pearring JN, Meire FM, et al. Mutations in TRPM1 are a common cause of complete congenital stationary night blindness. The American Journal of Human Genetics. 2009;85(5):730-6.

Dryja TP, McGee TL, Berson EL, Fishman GA, Sandberg MA, Alexander KR, et al. Night blindness and abnormal cone electroretinogram ON responses in patients with mutations in the GRM6 gene encoding mGluR6. Proceedings of the National Academy of Sciences. 2005;102(13):4884-9.

Bech-Hansen NT, Naylor MJ, Maybaum TA, Sparkes RL, Koop B, Birch DG, et al. Mutations in NYX, encoding the leucine-rich proteoglycan nyctalopin, cause X-linked complete congenital stationary night blindness. Nature genetics. 2000;26(3):319-23.

Gregg RG, Mukhopadhyay S, Candille SI, Ball SL, Pardue MT, McCall MA, et al. Identification of the gene and the mutation responsible for the mouse nob phenotype. Investigative ophthalmology & visual science. 2003;44(1):378-84.

Lu LJ, Liu J, Adelman RA. Novel therapeutics for Stargardt disease. Graefe's Archive for Clinical and Experimental Ophthalmology. 2017;255:1057-62.

Binley K, Widdowson P, Loader J, Kelleher M, Iqball S, Ferrige G, et al. Transduction of photoreceptors with equine infectious anemia virus lentiviral vectors: safety and biodistribution of StarGen for Stargardt disease. Investigative ophthalmology & visual science. 2013;54(6):4061-71.

Mukherjee N, Schuman S, Fekrat S, Scott I. Diagnosis and management of Stargardt disease. Eyenet. 2014:29-31.

Heath Jeffery RC, Chen FK. Stargardt disease: Multimodal imaging: A review. Clin Exp Ophthalmol. 2021;49(5):498-515.

Fujinami K, Zernant J, Chana RK, Wright GA, Tsunoda K, Ozawa Y, et al. Clinical and molecular characteristics of childhood-onset Stargardt disease. Ophthalmology. 2015;122(2):326-34.

Tanna P, Georgiou M, Aboshiha J, Strauss RW, Kumaran N, Kalitzeos A, et al. Cross-sectional and longitudinal assessment of retinal sensitivity in patients with childhood-onset Stargardt disease. Translational Vision Science & Technology. 2018;7(6):10-.

Tanna P, Georgiou M, Strauss RW, Ali N, Kumaran N, Kalitzeos A, et al. Cross-sectional and longitudinal assessment of the ellipsoid zone in childhood-onset Stargardt disease. Translational Vision Science & Technology. 2019;8(2):1-.

Heath Jeffery RC, Mukhtar SA, McAllister IL, Morgan WH, Mackey DA, Chen FK. Inherited retinal diseases are the most common cause of blindness in the working-age population in Australia. Ophthalmic Genetics. 2021;42(4):431-9.

Tsybovsky Y, Molday RS, Palczewski K. The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. Inflammation and retinal disease: complement biology and pathology. 2010:105-25.

Quazi F, Lenevich S, Molday RS. ABCA4 is an N-retinylidene-phosphatidylethanolamine and phosphatidylethanolamine importer. Nature communications. 2012;3(1):925.

Tsang SH, Sharma T. Stargardt disease. Atlas of Inherited Retinal Diseases. 2018:139-51.

Heath Jeffery RC, Chen FK. Stargardt disease: Multimodal imaging: A review. Clinical & Experimental Ophthalmology. 2021;49(5):498-515.

Pajic B, Weigell-Weber M, Schipper I, KRYENBüHL C, BüCHI ER, Spiegel R, et al. A novel complex mutation event in the peripherin/RDS gene in a family with retinal pattern dystrophy. Retina. 2006;26(8):947-53.

Tsai A, Koh A, Wang N-K, Mathur R, Cheung GC. Pattern Dystrophy. Hereditary Chorioretinal Disorders. 2020:75-84.